PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in <i>Ph</i>(-) Myeloproliferative Neoplasm: A Review

PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in <i>Ph</i>(-) Myeloproliferative Neoplasm: A Review

There has been significant progress in immune checkpoint inhibitor (CPI) therapy in many solid tumor types. However, only a single failed study has been published in treating <i>Ph(</i>-) myeloproliferative neoplasm (MPN). To make progress in CPI studies on this disease, herein, we revie...

Full description

Bibliographic Details
Main Authors: Jen-Chin Wang, Lishi Sun
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:International Journal of Molecular Sciences
Subjects:
myeloproliferative neoplasm
myeloid-derived suppressor cells
PD-1
PD-L1
myeloid suppressor cells (MDSC)
immune checkpoint inhibitor therapy (CPI)
Online Access:https://www.mdpi.com/1422-0067/23/10/5837

Internet

https://www.mdpi.com/1422-0067/23/10/5837

Similar Items